NCT01216839

Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Sidnei Epelman · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the Everolimus aim response in children and adolescents with refractory or relapsed Rhabdomyosarcoma and other soft tissue sarcomas

Conditions

• Refractory or Relapsed RMS and Soft Tissue Sarcomas

Interventions

Type	Name	Description
DRUG	Everolimus	Everolimus will be administered every day, initial dose 5 mg/m²/day, in 28 days cycle. Maximum dose: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.

Timeline

• Start date: 2011-03-01
• Primary completion: 2013-10-01
• Completion: 2013-12-01
• First posted: 2010-10-07
• Last updated: 2013-03-26

Locations

1 site across 1 country: Brazil